Relcobatinib Paper Maps Selective BCR ABL1 Binding

Previously missed November 3 online Leukemia article describes the structure and preclinical selectivity of relcobatinib (ELVN-001), an active-site BCR::ABL1 inhibitor already in CML clinical trials. The publication adds mechanistic evidence; it is not a…





